Similar documents
Prevention of transmission of HIV and other bloodborne viruses in healthcare and post exposure prophylaxis. John Ferguson, UPNG 2012

HPTN 073: Black MSM Open-Label PrEP Demonstration Project

Getting to Know PrEP (Pre-Exposure Prophylaxis)

POST EXPOSURE PROPHYLAXI S

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)

4/15/2010. Vermont Department of Health STD/HIV Program Vermont Department of Health STD/HIV Program. Vermont Department of Health STD/HIV Program

Pre-exposure prophylaxis (PrEP)

GUIDELINES FOR THE MANAGEMENT OF A PERCUTANEOUS OR SEXUAL EXPOSURE TO BLOODBORNE PATHOGENS DEPARTMENT OF HEALTH AND WELLNESS PRINCE EDWARD ISLAND

Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers

POSTEXPOSURE PROPHYLAXIS

FAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease.

HIV Guidelines. New Strategies.

Hepatitis C. Screening, Diagnosis and Linkage to Care

HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD

POST EXPOSURE MANAGEMENT: HEPATITIS B, HEPATITIS C AND HIV

POST-EXPOSURE PROPHYLAXIS (HIV, HEP B, HEP C)

Patient Information Sheet

Title: Post Exposure Prophylaxis Page 1 of 8 Policy No: 1 CLN 010 Effective Date 04/15/11

HIV. Looking after your sexual health

Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013

Guidelines for Nurse Led HIV Clinic

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline

July 3, III. VA policy:

Injection Drug Users in Miami-Dade: NHBS-IDU2 Cycle Preliminary Results

Increase of sexually transmitted hepatitis C virus in HIV+ men who have sex with men in Barcelona, Spain. A problem linked to HIV infection?

Appendix 3 Exposure Incident Report Form

Post-Exposure Prophylaxis after Non-Occupational and Occupational exposure to HIV. National Guidelines

ABI Consumer Guide for gay men on HIV and Life Insurance

Protocol for Needle Stick Injuries Occurring to NY Medical College Students In Physicians Offices

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014

Integrated Post-exposure Protocol for HIV, HBV and HCV: Guidelines for Managing Exposures to Blood and Body Fluids

Stefan R. Rowniak, PhD, RN, MS, FNP. University of California, San Francisco, CA. University of California, San Francisco, CA

Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management

How testing and treatment can stop HIV. Information for gay and bisexual men.


When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

Offering HIV Post-Exposure Prophylaxis (PEP) Following Non-Occupational Exposures

Belgian development agency

TOOLS, TRENDS AND NEW TECHNOLOGIES IN HIV PREVENTION

Postexposure Prophylaxis (PEP)

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Multiple Sclerosis Agents

AAB 2013 Annual Meeting & Educational Conference

Estimates of New HIV Infections in the United States

Instructions for Abroad Clinical Rotation

Non-Academic Program Assessment Form Assessment Cycle:

UWHC GME Global Health Emergency Plan

Guidelines for Blood borne Pathogen Exposure and Post Exposure Prophylaxis at Global Health Field Sites

Needle-Stick Policy.

SPECIALTY PROVIDER MANUAL

HIV-Associated Risk Behaviour Among Drug Users at Drug Rehabilitation Centres

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

Q and A for PARTNER Studies: Interim analysis results presented at CROI CROI presentation can be found at

Condoms for the prevention of HIV and STI transmission

HIV/AIDS: General Information & Testing in the Emergency Department

HIV Infection Among Those with an Injection Drug Use*-Associated Risk, Florida, 2014

Transcending Barriers for Safer Pleasure

UNAIDS 2014 LESOTHO HIV EPIDEMIC PROFILE

Hepatitis A/B Vaccination of inmates in the Los Angeles County Jail

Module 7: The Role of the Nurse

WISCONSIN AIDS/HIV PROGRAM NOTES

UK Guideline for the use of HIV Post-Exposure Prophylaxis Following Sexual Exposure (PEPSE)

Post-Exposure Prophylaxis (PEP) Guidelines for children and adolescents potentially exposed to blood-borne viruses

Therapeutic Guidelines. Accidental exposure guidelines

(C) Deep injury and those caused by hollow bore needles, where more potential transference of blood is involved.

Instructions for Clinical Rotation Abroad

Clinical Infectious Diseases Advance Access published September 1, 2015

UNIVERSITY OF KENTUCKY HEALTH CARE COLLEGES POLICY ON EDUCATIONAL EXPOSURE TO BLOOD BORNE PATHOGENS

HIV, Hepatitis B, Hepatitis C and Sexually Transmitted Infections

04/06/2015. Aaron V. Sapp, MD, MBA University of Missouri Columbia Student Health Center

Guidelines for Viral Hepatitis CTR Services

POST-EXPOSURE PROPHYLAXIS IN THE HEALTH CARE SETTING

The Basics of Drug Resistance:

12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS

New York State Department of Health Immunization Program Combined Hepatitis A and B Vaccine Dosing Schedule Policy

How To Improve Health Care For An Hiv Patient

Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States

Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* Overview. To change category names: Instructions. 2. Introduce session.

CRISP1 Data Archive. The NIDDK Repository offers the following three data packages from the CRISP1 study:

Handling of recommendations etc. from each accident investigation committee

Guidelines for. Blood-borne Pathogen Exposure and Post-Exposure Prophylaxis in Global Health Field Sites

HIV Prophylaxis For Adults After Sexual Assault. Recommendations for Health Care Providers

Problems and Measures Regarding Waste 1 Management and 3R Era of public health improvement Situation subsequent to the Meiji Restoration

OHIO ATTORNEY GENERAL SEXUAL ASSAULT FORENSIC EXAMINATION (SAFE) PROGRAM INSTRUCTIONS FOR REIMBURSEMENT FORM

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

The Epidemiology of Internet Sex Partnering and Intervention Use, California

A publication for men who have sex with men. Is taking PrEP the right choice for you? your life matters

BLOOD AND BODY FLUID EXPOSURE MANAGEMENT TOOL

Frequently Asked Questions (FAQs)

Understanding the HIV Care Continuum

United States Department of Justice. Best Practices Guide to Reform HIV Specific Criminal Laws to Align with Scientifically Supported Factors

HIV futures six Making Positive Women s Lives Count

Quick Guide. For Clinicians. Based on TIP 37 Substance Abuse Treatment For Persons With HIV/AIDS

SHARPS INJURY POLICY

Assertive outreach enhances hepatitis B vaccination for people who inject drugs in Melbourne, Australia

The Role of New Media on Sexual Health

BASIC INFORMATION ABOUT HIV, HEPATITIS B and C, and TUBERCULOSIS Adapted from the CDC

Chlamydia THE FACTS. How do people get Chlamydia?

UNITED NATIONS GENERAL ASSEMBLY SPECIAL SESSION ON HIV/AIDS. Country Progress Report Sweden

Burton Hospitals NHS Foundation Trust. Corporate / Directorate. Clinical / Non Clinical. Department Responsible for Review:

Transcription:

A Gay Men s Health Service Audit of: Post Exposure Prophylaxis Robert Obara, BSc MPH MBBChBAO Candidate, TCD Class of 2014 Poster for BASHIV, Dr Dominic Rowley (GMHS) et al.

PEP Talk Antiretroviral drugs (Truvada + Kaletra) Within 72 hours of HIV exposure Must be taken for 4 weeks Free of charge Side effects often experienced GMHS PEP Audits Main audit: July 2011 October 2011 Compiled demographics Evaluated clinical management Re-audit competed spring 2013

PEP Recipient Demographics } 52 PEP recipients were identified 31 from the first audit & 21 from the re-audit } All were MSM }

Reason for requesting PEP HIV Risk 13% (n=7) documented partner as HIV positive (3 of 7 documented partner taking HAART) Majority unaware of their partners status 27% (n=14) reported condom accidents No cases of non consensual sex were documented Majority were documented as consensual unprotected intercourse with a casual partner

1 st Clinical Review Findings 87% (n=27) had baseline HIV bloods documented 90% (n=29) received Truvada and Kaletra 77% (n=24) completed the full course Reasons for non-completion included discovery of partner HIV status, PEP side effect intolerance, anxiety, and limited HIV exposure 77% (n=24) had a 4 week follow-up HIV test 67% (n=21) had a 12 week test All 31 patients tested HIV negative at subsequent blood tests

Re-Audit of Clinical Practice 100% (n=21) had baseline HIV test 95% (n=20) had Hep B immunity status documented 90% (n=19) had Hep C result within the past 2 years Decrease in PEP prescriptions for insertive anal only No seroconversions were discovered Noted inconsistencies in the timing of follow up HIV tests (1 12 weeks) and lab tests (FBCs and LFTs) Thus standardized clinical protocol and patient leaflets

PatientInformationLeafletonPEPSE HighRiskPack Youarebeingstartedoncombinationanti viraldrugs.thisistohelppreventhiv afterpossiblesexualexposuretothehivvirus. Thedrugsintwoseparateproducts(colouredtablets)willbeprescribedforatotalof 28Days. Youhavereceivedan8daypack.YoumustattendyournextappointmentatGMHS toobtaintherestofthesupply,beforethe8daysupplyrunsout. Pleasetrynottomissanydoses.Ifyouforgettotakeadose,takeitassoonasyou rememberandthenextdoseatthenormaltime.nevertakeadoubledose. PleasecheckwithyourdoctorattheGMHSabouttakinganynewmedications (prescriptionornonprescription)whilstonthiscombinationtherapy. ContactTelephoneNumber:GMHS01 6699553 DateofPrescription: Doctor: Appointments&Procedures. 1 st Appointment:(7or8daysfromtoday): RestofTabletsandBloodTests:LFT/FBC/Renal. 2 nd Appointment:6WeeksfromprescriptionDate ST Is cre ena n dbl oo d Tes t s: (HIV,HEPC,Syphilis). 3 rd Appointment:12WeeksfromprescriptionDate: FinalBloodTests:(HIV,HEPC,Syphilis). DrugsDescription TRUVADA (BlueTablet) TakeisONEtabletperDAY,withfood. TheTRUVADA tabletcontains2differentdrugs Tenofovir(Ten)andEmtricitabine (FTC).Itisusuallywelltolerated. Possiblesideeffectsincludeachesandpains,dizziness,headaches,diarrhoea, nausea,vomitingandinsomnia.(therearetabletstohelpwiththisseebelow) KALETRA (PaleYellowTablet) TakeTWOtabletsTWICEaday(every12Hours),withorwithoutfood. TheactivedruginKaletra islopinavir.asmalldoseofanadditionaldrug,ritonavir, isincludedtoincreasethebloodlevelsoflopinavir. ThemostcommonsideaffectsofKALETRA arediarrhoeaandincreasedcholesterol. Headache,insomnia,gastrointestinaleffectsandchangesinbloodsugarsorliver enzymesmayalsooccur. TherearesomemedicationsthatcannotbetakenwhenonKALETRA Itisimportanttotellthedoctorandpharmacistaboutanyothermedications (prescriptionornonprescription)youarecurrentlytaking. Helpfulhints: (BLUEtablet:onceperday) (Pale/Yellowtablet:2twiceperdaymorningandevening) OthermedicationbelowtohelpyouwhiletakingPEP Thesecanbeboughtatachemistwithoutprescription Imodium2mgCapsules Anti DiarrhoeaTabletstotakeasneededdaily Motilium10mgTablets Anti NauseaTablets Take2tablets,30minutesbeforetheothertabletsprescribed.Morningandevening forthemonthasnecessary. Paracetamol(takeasdirectedonpack) Thisisasuitablepainkillertotakeforheadache,achesorpains